Zim Laboratories Ltd Q4 FY2023 Concall Summary

Key Takeaways

• FY23 delivered strong PAT growth of 67.2% YoY to ₹24.4 crore, driven by operating leverage and a sharp reduction in finance costs as debt fell.
• Export momentum is the engine: exports grew 25.2% YoY, now 85% of revenue, but the regulated-market contribution is still only 7–8%, leaving a long runway for the NIP and OTF pipeline.
• The company is at a self-described inflection point: ₹84 crore of R&D spend over four years has built a pipeline of value-added generics using proprietary platforms, but most results are yet to materialize.
• Margins improved 110 bps to 14.7% EBITDA, with management signaling further upgrade potential when NIP and high-value regulated products begin contributing, though no specific targets were given.
• What to watch next quarter: the pace of EU dossier submissions and out-licensing income, the first revenue from OTF products in Europe, and any quantification of the regulated-market pipeline.

Financial Performance

• Revenue growth: FY23 top line grew 20% YoY, with Q4 FY23 operating income up 4.4% QoQ to ₹105.4 crore, driven by process innovation and differentiation in difficult-to-manufacture products.
• Profitability leap: PAT grew 67.2% YoY to ₹24.4 crore, helped by a finance cost decline from ₹8.3 crore to ₹5.6 crore as borrowings were cut from ₹89.9 crore in FY20 to ₹59.6 crore in FY23.
• Margin expansion: EBITDA margin improved 110 bps to 14.7% in FY23, supported by product mix and operating efficiencies; Q4 EBITDA margin was stable at 15.3%.
• Gross margin stability: Sustained gross margin improvement over recent quarters is attributed to product and market mix; existing business gross margins are expected to remain stable.
• R&D intensity: 6.6% of revenue was invested in R&D during FY23; absolute R&D spend will stay at similar levels, though it may decline slightly as a percentage of revenue as the top line grows.
• Debt and interest costs: A better credit rating has brought the cost of debt down to around 10.5%; management expects no material change in debt levels absent major CapEx.

The Regulated-Market Pipeline: NIP and OTF

• The core bet: future growth and margin upgrade are tied to Novel Innovative Products (NIP) and Oral Thin Film (OTF) products entering regulated markets, primarily Europe, with the existing RoW and MENA business continuing at upper-teen growth.
• NIP competitive positioning: products are value-added generics using Zim's patented alternative technologies, designed to remove drawbacks of the innovator product; one submitted product has genericized with limited competition, the second has not been genericized at all, and many will face formulation patent hurdles even after API patent expiry.
• NIP filing strategy: products are filed approximately 1–1.5 years before patent expiry to be in the race for generic approval, targeting molecules going off patent in 2024, 2025, and 2026.
• NIP revenue timeline: filings are already done; approvals normally take around 18–24 months, with revenue from manufacturing and supply agreements expected by end of 2024, while licensing fees start sooner.
• OTF progress: the division secured a second EU marketing authorization for Sildenafil Citrate orally disposable strip in Spain; Rizatriptan and Sildenafil Citrate are already authorized, and revenue from these may start in Q2 or maximum by Q3 of FY24.
• OTF market context: the technology addresses an \$8 billion market but is still at a nascent stage for pharmaceuticals, with most action so far in nutraceuticals; RoW and India are price-sensitive follow-on markets, so growth has been low at 12% from FY20 to FY23.
• Out-licensing model: three stages — co-development, out-license dossiers without filing on own, or file and wait for the right partner before transferring the marketing authorization and entering a distribution and supply agreement.
• Dossier and out-licensing income: revenue from dossier fees and out-licensing is expected to start in Q1 or Q2 FY24 for some products, including Oral Thin Films, though management declined to quantify the amounts.

Chandrasekhar Mainde: "We are using the alternative technologies which are our patented technology. That gives a better product than the existing generic product... our products are generally coming with the removing the drawbacks of the existing reference, what we call the innovator product and adding value. So, we can call our products as a value-added generic."

Regulatory and Dossier Momentum

• FY23 dossier activity: 56 dossiers filed and 44 registrations received; two products submitted in the EU based on Micro Emulsion Coating Technology and Pellet Cold Forming Technology, accepted as generic submissions.
• EU partner approvals: EU partners obtained five marketing authorizations on Zim's dossier; supply agreements exist with all partners who have obtained MA using Zim's dossier, though management declined to share projections.
• FY24 submission plan: Q1 — two submissions in Europe; Q2 — two submissions in Europe plus some highly regulated South American markets; Q4 — three submissions; approximately 10 submissions total through end of FY24.
• Facility readiness: facilities are EU GMP approved with almost 15 different approvals; specialized suites for NIP products will be taken over this year, with completion targeted by early next year, and EU approval will follow without a separate application since the expansion is within existing premises.
• Regulated market targets: beyond Europe, the company is targeting Australia, highly regulated South American markets, and some EU-related regulated markets.

Business Model and Market Mix

• Export dominance: export business grew 25.2% YoY to ₹338.2 crore, contributing 85% of total operating income, driven by RoW and MENA markets.
• Regulated market share: present regulated-market revenue is not more than 7–8% of the total; management expects this to double to 15–20% in the coming few years as NIP and OTF products gain traction.
• Pharma vs. nutraceutical mix: the 75%-25% ratio is expected to continue for some time; a new greenfield nutraceutical plant is planned, with upgradation and de-bottlenecking projects underway to increase capacity.
• Domestic business: the company is looking at the Indian market through an OTC business and an e-commerce launch being ideated for the ODS business, nutra, and domestic market, with more details promised in future quarters.
• Currency and inflation: some challenges exist from currency and inflation in operating countries, but management's experience is that these smoothen out over time in the pharmaceutical business.

Anwar Daud: "We are continuing on our journey of transformation of the company. And the transformation is all around in the terms of moving up the value chain, moving up the regulatory chain, going into markets where we have not been present before, working on the products which are complex and where the competition space is favorable to the company..."

CapEx and Infrastructure

• FY23 CapEx: most spending was on the warehouse (₹11.7 crore), with the remainder on capacity balancing and packing belt capacity.
• Warehouse expansion: nearing completion.
• Future CapEx: expected to be on similar lines, done according to market requirements and growth pace; no separate big CapEx plan or new facility is required for growth, as the existing facility can manage with the CapEx plan already under process.
• Automation: the expansion includes automation of the packaging line.
• Debt capacity: bank sanctions and debt sanctions are already available if CapEx is required; a clearer picture is expected by next quarter.

Margin Trajectory and Caution

• Upgrade driver: margins can see an upgrade when NIP products and high technical value products from regulated markets come in; existing business gross margins are expected to be stable, with the company aiming to remain a competitive player in RoW and MENA.
• No numerical targets: management is wary of giving specific calls on how much margins will improve, citing the pharmaceutical business's long-distance nature — approvals take time, and the competitive landscape can shift by the time they arrive.
• Intent stated: the intention is to increase margin and grow in the right direction, but the trajectory depends on regulatory outcomes and market conditions that are not fully within the company's control.

Anwar Daud: "Pharmaceutical is a long distance business. Approvals come in, when the approvals come in there can be a different competitive landscape. So, that is why we are very wary of giving these kind of specific calls on by how much and what will it be actually but that is the intention that is the general trajectory in which the company is growing itself."

Guidance & Commitments

Key Metrics